Amryt Pharma Current Ratio 2019-2021 | AMYT

Amryt Pharma current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Amryt Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.22B $0.10B 2.19
2021-03-31 $0.20B $0.09B 2.14
2020-12-31 $0.20B $0.10B 2.01
2020-09-30 $0.00B 0.00
2020-06-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.16B $0.10B 1.57
2018-12-31 $0.02B $0.01B 1.60
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.747B $0.183B
Amryt Pharma plc is a biopharmaceutical company. It develops and commercializes therapeutics to treat rare diseases. Amryt Pharma plc is based in London, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00